LH: What This Test Actually Measures

What LH Actually Is and Where It Comes From

LH is a 28 to 30 kDa glycoprotein secreted in pulses by gonadotroph cells in the anterior pituitary. It shares an alpha subunit with FSH, TSH, and hCG; its beta subunit is unique and determines receptor specificity. The hypothalamus controls release through gonadotropin-releasing hormone (GnRH) pulses, which arrive roughly every 60 to 90 minutes in healthy adults. Endocrine Society clinical practice guidelines on hypogonadism describe this axis in detail.

The Hypothalamic-Pituitary-Gonadal Axis

The HPG axis works as a feedback loop. GnRH from the hypothalamus stimulates LH secretion; LH acts on gonads; sex steroids feed back to the hypothalamus and pituitary. When gonadal output falls, LH rises. When gonadal output is adequate, LH falls. This feedback logic is exactly why a single LH value can localize a hormonal problem.

How LH Is Secreted

Because GnRH is pulsatile, so is LH. A single serum draw captures one snapshot in time. Pulsatile amplitude increases during the follicular phase and during puberty. Stress, sleep deprivation, and extreme caloric deficit all suppress GnRH pulse frequency, secondarily lowering LH. A 2017 review in the Journal of Clinical Endocrinology and Metabolism confirmed that energy availability directly modulates GnRH pulse generator activity.

Why the Beta Subunit Matters for Assays

Most modern immunoassays target the beta subunit to avoid cross-reactivity with hCG, which is critical in pregnancy and in patients receiving hCG as a therapeutic agent. Clinicians ordering LH on a patient taking exogenous hCG should flag this to the lab, because some older assays will report falsely elevated LH.

What LH Measures Differently in Males vs. Females

The biological function of LH differs by gonadal tissue, so the clinical interpretation of a result depends on the patient's sex and reproductive status. Same hormone, different targets.

LH in People With Testes

In testicular tissue, LH binds Leydig cell receptors and stimulates the conversion of cholesterol to testosterone via the steroidogenesis pathway. Normal serum LH in adult males is 1.7 to 8.6 IU/L; normal total testosterone is 300 to 1,000 ng/dL. The 2018 Endocrine Society guideline on male hypogonadism specifies these thresholds. When testosterone is low and LH is also low, the problem is upstream (secondary hypogonadism). When testosterone is low and LH is high, the testes themselves are failing (primary hypogonadism). This two-step logic guides every workup for male hormone deficiency.

LH in People With Ovaries

In ovarian tissue, LH acts on theca cells to produce androgens that granulosa cells then aromatize to estrogens. The critical event is the LH surge: a sharp, brief spike in LH (often exceeding 40 IU/L) that triggers follicle rupture and ovulation approximately 36 to 40 hours later. A 2021 paper in Human Reproduction quantified the LH surge onset-to-ovulation interval at a median of 32 hours (95% CI 24 to 56 hours) across 138 natural cycles. Home ovulation predictor kits detect this same surge in urine.

LH in Postmenopausal Individuals

After menopause, ovarian follicular reserve is depleted. Estradiol falls, negative feedback is removed, and both LH and FSH climb substantially. A postmenopausal LH consistently above 10.9 IU/L (often 20 to 60 IU/L) is physiologically normal. Ordering LH to diagnose menopause is reasonable when menstrual history is ambiguous or when premature ovarian insufficiency is suspected before age 40.

Normal LH Ranges by Life Stage and Sex

Reference intervals vary by assay and lab, but the values below reflect consensus from multiple published sources and FDA-cleared assay package inserts.

Male Reference Intervals

| Life Stage | LH (IU/L) | |---|---| | Prepubertal (<9 years) | <0.5 | | Pubertal onset | 0.3 to 5.3 | | Adult male | 1.7 to 8.6 | | Older adult male (>65 years) | 3.1 to 12.0 |

The Endocrine Society's 2010 testosterone therapy guidelines note that reference ranges differ substantially between second-generation immunoassays and liquid chromatography-mass spectrometry methods.

Female Reference Intervals

| Reproductive Phase | LH (IU/L) | |---|---| | Follicular phase | 1.9 to 12.5 | | Midcycle surge | 8.7 to 76.3 | | Luteal phase | 0.5 to 16.9 | | Postmenopausal | 10.9 to 58.6 |

These ranges reflect the Abbott ARCHITECT assay, one of the most widely used platforms in U.S. Commercial labs. Results from different platforms are not directly interchangeable. A 2019 analysis in Clinical Chemistry showed inter-assay LH variation of up to 30% for the same sample across five immunoassay platforms.

Pediatric LH and the GnRH Stimulation Test

In prepubertal children, basal LH is nearly undetectable. The GnRH (or leuprolide) stimulation test is the diagnostic standard for precocious puberty: a peak LH >5 IU/L after stimulation indicates central (gonadotropin-dependent) precocious puberty. A 2019 review in the Journal of Clinical Endocrinology and Metabolism outlines stimulation test protocols for this age group.

What a High LH Result Means

An elevated LH, interpreted alongside testosterone or estradiol, points to the gonad rather than the brain. This is the key diagnostic branch point.

Primary Hypogonadism (Hypergonadotropic)

When LH is high and testosterone (males) or estradiol (females) is low, the gonad is not responding to adequate stimulation. The pituitary is working; the end organ is not. Causes include Klinefelter syndrome (47,XXY), chemotherapy or radiation gonadotoxicity, autoimmune oophoritis, and Turner syndrome. The 2018 Endocrine Society male hypogonadism guideline recommends karyotype analysis when primary hypogonadism is confirmed and cause is unclear.

Polycystic Ovary Syndrome

An LH:FSH ratio above 2:1 or 3:1 in a reproductive-age female with oligomenorrhea raises suspicion for PCOS. The 2023 international PCOS evidence-based guideline notes that LH:FSH ratio is no longer listed as a diagnostic criterion but remains useful for phenotyping and understanding androgen excess. The 2023 PCOS guideline published jointly by Endocrine Society and European Society of Endocrinology states: "Elevated LH concentrations and an elevated LH/FSH ratio are a frequent finding in PCOS and reflect disrupted GnRH pulsatility rather than primary pituitary disease." That pulsatility disruption is driven by reduced progesterone feedback during anovulatory cycles.

Menopause and Premature Ovarian Insufficiency

A single LH above 40 IU/L with amenorrhea for 12 months confirms menopause in most clinical scenarios. Premature ovarian insufficiency (POI) is diagnosed when LH (and FSH) are in the menopausal range before age 40, confirmed on two draws at least 4 weeks apart. The 2016 European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends FSH >25 IU/L on two occasions as the diagnostic threshold, with LH providing corroborating evidence.

How to Lower LH: Clinical Approaches

When high LH drives unwanted downstream effects (e.g., excess androgen in PCOS, accelerated follicle depletion), clinicians have several tools:

• Combined oral contraceptives. Estrogen and progestin suppress GnRH pulsatility, reducing both LH and FSH. LH suppression to <1 IU/L is typical during active pill days.
• GnRH agonists (leuprolide, triptorelin). Initial agonist-phase causes an LH flare, then receptor downregulation drops LH to castrate levels within 3 to 4 weeks. Used in endometriosis, prostate cancer, and IVF protocols.
• GnRH antagonists (cetrorelix, ganirelix). Immediate competitive blockade of GnRH receptors. LH falls within hours. Standard in controlled ovarian stimulation cycles to prevent premature luteinization.

A 2020 Cochrane review on GnRH antagonist protocols in IVF (40 trials, N=7,511) found comparable live birth rates to agonist long protocols with fewer ovarian hyperstimulation syndrome cases.

What a Low LH Result Means

Low LH with low sex steroids is the hallmark of secondary (central) hypogonadism. The gonad is capable of producing hormones; it simply is not receiving adequate stimulation.

Secondary Hypogonadism in Males

Causes include hyperprolactinemia (prolactin >200 ng/mL almost always suppresses GnRH), pituitary adenoma, hemochromatosis, opioid use (chronic opioids suppress GnRH in 21 to 86% of patients by published estimates), exogenous androgen use, and functional hypothalamic hypogonadism from caloric restriction or excessive exercise. A 2014 study in Pain Medicine found that 74% of men on long-term opioid therapy had testosterone below 300 ng/dL, with correspondingly low LH values.

Functional Hypothalamic Amenorrhea in Females

Relative energy deficiency in sport (RED-S) and eating disorders suppress GnRH pulsatility. LH falls below 1 IU/L, FSH may be low-normal, and estradiol drops below 50 pg/mL. The 2014 Female Athlete Triad Coalition consensus statement links low energy availability directly to LH pulse suppression and bone loss risk.

Kallmann Syndrome and Congenital GnRH Deficiency

Kallmann syndrome (anosmia plus hypogonadotropic hypogonadism) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) both present with LH <1 IU/L and absent or incomplete puberty. The GnRH stimulation test typically produces a blunted LH response. The 2019 Endocrine Society guideline on congenital hypogonadotropic hypogonadism specifies LH <1 IU/L with testosterone <100 ng/dL as the biochemical constellation requiring genetic workup.

How to Raise LH: Clinical Approaches

When low LH drives hypogonadism and fertility is desired, stimulating the HPG axis is preferable to replacing sex steroids directly (which suppresses LH further).

• Clomiphene citrate (clomifene). An estrogen receptor antagonist at the hypothalamic level. It blocks negative feedback, raising GnRH pulse frequency and thus LH and FSH. Typical male dose: 25 to 50 mg every other day. Females: 50 to 150 mg on days 3 to 7 of cycle. A 2019 systematic review in Fertility and Sterility (17 studies, N=1,211) found clomiphene raised testosterone in hypogonadal men by a mean of 251 ng/dL while preserving fertility compared to TRT.
• Enclomiphene. The trans-isomer of clomifene, with less estrogenic effect. Studies show LH increases from a mean of 3.2 to 6.4 IU/L at 12.5 mg/day. FDA has not yet approved enclomiphene as of the 2025 publication date.
• Human chorionic gonadotropin (hCG). hCG is structurally similar to LH and binds LH receptors. Used in males with secondary hypogonadism to maintain testicular volume and spermatogenesis. Dose range: 500 to 5,000 IU subcutaneously two to three times per week.
• Pulsatile GnRH therapy. Delivered via subcutaneous pump at 5 to 20 mcg per pulse every 90 minutes; restores endogenous LH pulsatility. Highly effective in Kallmann syndrome and IHH. A 2020 review in the New England Journal of Medicine on male reproductive endocrinology describes pulsatile GnRH as the closest approximation to restoring physiologic HPG axis function.
• Weight restoration and energy adequacy. In functional hypothalamic hypogonadism, correcting caloric deficit is first-line. LH pulsatility resumes before estradiol fully normalizes in most cases.

LH in the Context of Fertility Workup

Fertility evaluation in both sexes relies on LH as one of at least four pituitary-gonadal markers. No single value is diagnostic in isolation.

Female Fertility Panel

A complete female fertility panel includes LH, FSH, estradiol, AMH, and a day-3 antral follicle count by ultrasound. Day-3 FSH >10 IU/L with a day-3 LH:FSH ratio >1 suggests diminished ovarian reserve or PCOS depending on the clinical picture. The American Society for Reproductive Medicine (ASRM) 2023 committee opinion on ovarian reserve testing states that no single marker outperforms a combination of AMH, AFC, and cycle-day FSH/LH.

Male Fertility Panel

In male infertility, LH combined with FSH, testosterone, and semen analysis defines etiology. Azoospermia with high LH and FSH points to non-obstructive azoospermia (testicular failure). Azoospermia with low LH and FSH points to secondary hypogonadism, where hCG or pulsatile GnRH can restore spermatogenesis in up to 80% of cases. A 2023 meta-analysis in Andrology (N=2,308 patients) confirmed that pre-treatment FSH <7.6 IU/L and testicular volume >6 mL predicted successful sperm retrieval in non-obstructive azoospermia.

LH Monitoring During Hormone Therapy

Clinicians treating patients with exogenous hormones need to understand how therapy changes LH values, because a suppressed LH is expected on-treatment and does not indicate a new pathology.

TRT and LH Suppression

Testosterone replacement therapy (TRT) via any route suppresses LH to near-zero within weeks. Exogenous testosterone saturates androgen receptors in the hypothalamus and pituitary, shutting down GnRH and thus LH secretion. Measuring LH while a patient is on TRT confirms compliance (low LH expected) but cannot assess endogenous HPG axis function until TRT is discontinued for at least 6 to 8 weeks. The 2018 Endocrine Society guideline on male hypogonadism states: "Serum LH and FSH are suppressed during testosterone therapy and therefore cannot be used to assess endogenous gonadotropin secretion while treatment is ongoing."

Estrogen and Progesterone Therapy in Females

Menopausal hormone therapy (MHT) does not target LH normalization; it replaces estradiol to address symptomatic deficiency. LH may fall modestly on systemic estrogen but does not normalize to premenopausal levels in most postmenopausal users. Checking LH during MHT is rarely clinically necessary unless POI is being monitored or pituitary pathology is suspected.

GLP-1 Receptor Agonists and LH

Emerging data suggest significant weight loss (15 to 20% body weight, as seen with semaglutide 2.4 mg in STEP-1 [N=1,961]) can restore LH pulsatility in women with obesity-related anovulation. STEP-1 showed 14.9% mean weight loss at 68 weeks vs. 2.4% placebo, with improvements in reproductive hormone profiles in a subset analysis. The mechanism is likely restoration of kisspeptin/GnRH pulse frequency as fat mass and leptin resistance decrease.

Pre-Test Considerations: When and How to Draw LH

Getting the timing and context right reduces interpretive ambiguity. A misread LH is often a misdraw.

Timing the Draw

In males, morning draws (07:00 to 10:00) minimize pulsatile noise. In females seeking a baseline, draw on cycle day 2 or 3. For suspected LH surge tracking, serial draws every 8 to 12 hours starting day 10 of a 28-day cycle, or use validated urine LH kits with confirmatory serum on a positive result.

Conditions That Confound Results

• Exogenous hCG: Cross-reacts with some LH assays. Flag the lab.
• Hyperprolactinemia: Suppresses LH; always measure prolactin alongside LH when secondary hypogonadism is suspected.
• Acute illness or hospitalization: Non-thyroidal illness syndrome and critical illness suppress the entire HPG axis; LH drawn during acute illness may be misleadingly low.
• Recent GnRH agonist injection: If a flare occurred within the prior 2 weeks, LH may be transiently elevated; post-downregulation LH should be <1 IU/L.

A 2022 guidance document from the American Association of Clinical Endocrinology (AACE) on laboratory testing in reproductive endocrinology emphasizes context-dependent interpretation and paired testing for all pituitary-gonadal markers.